These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
229 related articles for article (PubMed ID: 26324996)
41. Mississippi mud in the 1990s: risks and outcomes of vancomycin-associated toxicity in general oncology practice. Elting LS; Rubenstein EB; Kurtin D; Rolston KV; Fangtang J; Martin CG; Raad II; Whimbey EE; Manzullo E; Bodey GP Cancer; 1998 Dec; 83(12):2597-607. PubMed ID: 9874468 [TBL] [Abstract][Full Text] [Related]
42. Association between colistin dose and development of nephrotoxicity. Lee YJ; Wi YM; Kwon YJ; Kim SR; Chang SH; Cho S Crit Care Med; 2015 Jun; 43(6):1187-93. PubMed ID: 25756417 [TBL] [Abstract][Full Text] [Related]
43. Elevated vancomycin trough is not associated with nephrotoxicity among inpatient veterans. Prabaker KK; Tran TP; Pratummas T; Goetz MB; Graber CJ J Hosp Med; 2012 Feb; 7(2):91-7. PubMed ID: 22086511 [TBL] [Abstract][Full Text] [Related]
44. Impact of total body weight on rate of acute kidney injury in patients treated with piperacillin-tazobactam and vancomycin. Rutter WC; Hall RG; Burgess DS Am J Health Syst Pharm; 2019 Aug; 76(16):1211-1217. PubMed ID: 31369116 [TBL] [Abstract][Full Text] [Related]
45. Determinants of vancomycin nephrotoxicity when administered to outpatients as a continuous 24-hour infusion. Chambers ST; Long M; Gardiner SJ; Chin PKL; Yi M; Dalton SC; Drennan PG; Metcalf SCL Int J Antimicrob Agents; 2020 Jun; 55(6):105972. PubMed ID: 32298746 [TBL] [Abstract][Full Text] [Related]
47. Nephrotoxicity in patients with vancomycin trough concentrations of 15-20 μg/ml in a pediatric intensive care unit. Cies JJ; Shankar V Pharmacotherapy; 2013 Apr; 33(4):392-400. PubMed ID: 23471688 [TBL] [Abstract][Full Text] [Related]
48. Trough concentration over 12.1 mg/L is a major risk factor of vancomycin-related nephrotoxicity in patients with therapeutic drug monitoring. Han HK; An H; Shin KH; Shin D; Lee SH; Kim JH; Cho SH; Kang HR; Jang IJ; Yu KS; Lim KS Ther Drug Monit; 2014 Oct; 36(5):606-11. PubMed ID: 24577126 [TBL] [Abstract][Full Text] [Related]
49. Impact of piperacillin/tazobactam on nephrotoxicity in patients with Gram-negative bacteraemia. Hall RG; Yoo E; Faust A; Smith T; Goodman E; Mortensen EM; Raza J; Dehmami F; Alvarez CA Int J Antimicrob Agents; 2019 Mar; 53(3):343-346. PubMed ID: 30415001 [TBL] [Abstract][Full Text] [Related]
50. Nephrotoxicity Risk and Clinical Effectiveness of Continuous versus Intermittent Infusion Vancomycin Among Patients in an Outpatient Parenteral Antimicrobial Therapy Program. Shakeraneh P; Fazili T; Wang D; Gilotra T; Steele JM; Seabury RW; Miller CD; Darko W; Probst LA; Kufel WD Pharmacotherapy; 2020 Apr; 40(4):357-362. PubMed ID: 32090347 [TBL] [Abstract][Full Text] [Related]
51. Relationship between vancomycin-associated nephrotoxicity and the number of combined nephrotoxic agents. Ueki T; Sanematsu E; Furuya Y; Shinohara Y; Murakami Y; Miyazaki A; Sakamoto Y; Nakashima MN; Nakashima M Pharmazie; 2020 Jun; 75(6):279-283. PubMed ID: 32539926 [TBL] [Abstract][Full Text] [Related]
52. Vancomycin Trough and Acute Kidney Injury: A Large Retrospective, Cohort Study. Hammoud K; Brimacombe M; Yu A; Goodloe N; Haidar W; El Atrouni W Am J Nephrol; 2016; 44(6):456-461. PubMed ID: 27788522 [TBL] [Abstract][Full Text] [Related]
53. Incidence and predictors of acute kidney injury associated with intravenous polymyxin B therapy. Kubin CJ; Ellman TM; Phadke V; Haynes LJ; Calfee DP; Yin MT J Infect; 2012 Jul; 65(1):80-7. PubMed ID: 22326553 [TBL] [Abstract][Full Text] [Related]
54. The Relationship of nephrotoxicity to vancomycin trough serum concentrations in a veteran's population: a retrospective analysis. Horey A; Mergenhagen KA; Mattappallil A Ann Pharmacother; 2012 Nov; 46(11):1477-83. PubMed ID: 23073306 [TBL] [Abstract][Full Text] [Related]
55. Individualized vancomycin dosing in obese patients: a two-sample measurement approach improves target attainment. Hong J; Krop LC; Johns T; Pai MP Pharmacotherapy; 2015 May; 35(5):455-63. PubMed ID: 26011138 [TBL] [Abstract][Full Text] [Related]
56. [Vancomycin nephrotoxicity: Frequency and mechanistic aspects]. Luque Y; Mesnard L Nephrol Ther; 2018 Apr; 14 Suppl 1():S133-S138. PubMed ID: 29606259 [TBL] [Abstract][Full Text] [Related]
57. Evaluation of a Pharmacist-Directed Vancomycin Dosing and Monitoring Pilot Program at a Tertiary Academic Medical Center. Marquis KA; DeGrado JR; Labonville S; Kubiak DW; Szumita PM Ann Pharmacother; 2015 Sep; 49(9):1009-14. PubMed ID: 25991831 [TBL] [Abstract][Full Text] [Related]
58. Incidence and risk factors influencing the development of vancomycin nephrotoxicity in children. McKamy S; Hernandez E; Jahng M; Moriwaki T; Deveikis A; Le J J Pediatr; 2011 Mar; 158(3):422-6. PubMed ID: 20888013 [TBL] [Abstract][Full Text] [Related]
59. Impact of pharmacist intervention on preventing nephrotoxicity from vancomycin. Masuda N; Maiguma T; Komoto A; Haruki Y; Sugiyama T; Kondo S; Teshima D Int J Clin Pharmacol Ther; 2015 Apr; 53(4):284-91. PubMed ID: 25740266 [TBL] [Abstract][Full Text] [Related]